Search

Displaying results 4591 - 4600 of 8967 in total
  1. Drug

    Encainide

    go.drugbank.com/drugs/DB01228
    ApprovedWithdrawn

    All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent hea...

  2. Drug

    Contusugene ladenovec

    go.drugbank.com/drugs/DB05322
    Investigational

    Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.

  3. Drug

    Limaprost

    go.drugbank.com/drugs/DB09211
    Investigational

    Prostaglandins have a wide variety of actions, including, but not limited to muscular constriction and mediation of inflammation. … Ono and DSP also discontinued the development of limaprost alfadex for the additional indication of cervical spondylosis in 2008 due to the failure to demonstrate the anticipated efficacy in a Phase II

  4. Drug

    Midomafetamine

    go.drugbank.com/drugs/DB01454
    IllicitInvestigational

    It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  5. Drug

    Ferrous ascorbate

    go.drugbank.com/drugs/DB14490
    ApprovedWithdrawn

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    3,3'-diindolylmethane

    go.drugbank.com/drugs/DB11875
    Investigational

    Diindolylmethane has been used in trials studying the prevention and treatment of SLE, Prostate Cancer, Cervical Dysplasia, Stage I Prostate Cancer, and Stage II Prostate Cancer, among others.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    RP01 is a novel anti-IgE immunotherapy for allergic individuals. … It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response.

  8. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). … Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.

  9. Drug

    Cyd dengue virus serotype 4 live (attenuated) antigen

    go.drugbank.com/drugs/DB15524
    ApprovedInvestigationalWithdrawn

    Mixtures: DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION, DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
  10. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    a greater affinity for free serum IgE and an altered sensitivity to IgE conformation. … Similar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer